Finance

Lists
Why is TNYA down 25.05%?
Dive Deeper
TNYA:NASDAQ
Tenaya Therapeutics Inc
$0.39
-25.05%
(-0.13) 1D
$0.40
+2.94% (+0.012)
Pre-market
Closed: Oct 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNYA...
Open
$0.50
High
$0.51
Low
$0.36
Mkt. cap
87.73M
Avg. vol.
2.73M
Volume
7.60K
52-wk high
$2.04
52-wk low
$0.36
EPS
-$0.53
Beta
2.87
Shares outstanding
224.23M
No. of employees
70
Open
$0.50
High
$0.51
Low
$0.36
Mkt. cap
87.73M
Avg. vol.
2.73M
Volume
7.60K
52-wk high
$2.04
52-wk low
$0.36
EPS
-$0.53
Beta
2.87
Shares outstanding
224.23M
No. of employees
70
News stories
From web sources and news partners
About Tenaya Therapeutics Inc
CEO-
Employees70
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitetenayatherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to TNYA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for TNYA in the last 3 months.
Highest
Current $0.39
$40.00 (+10,143.28%)
Average
$13.00 (+3,229.07%)
Lowest
$3.00 (+668.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$3.00
+668.2%
10/05/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$5.00
+1,180.4%
08/06/2026
Cory Jubinville, PhD
LifeSci Capital
Buy
Maintained
$4.00
+924.3%
08/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$40.00
+10,143.3%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
07/29/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$2.00
+412.2%
06/03/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$8.00
+1,948.7%
05/15/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
-$0.09 / -$0.07
-35.90%miss
Revenue / Est. (USD)
1.11M / 10.00M
-88.90%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
225.00K
1.11M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
15.36M
14.80M
14.84M
16.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.57M
5.98M
5.45M
5.41M
Operating expense
20.94M
20.78M
20.29M
22.01M
Total operating expenses
20.94M
20.78M
20.29M
22.01M
Operating income
-20.94M
-20.78M
-20.06M
-20.90M
Other non operating income
3.00K
25.00K
-
-1.37M
EBT including unusual items
-20.28M
-20.18M
-19.27M
-43.39M
EBT excluding unusual items
-20.28M
-20.18M
-19.27M
-21.57M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.28M
-20.18M
-19.27M
-43.39M
Net profit margin
-
-
-8,565.33%
-3,909.28%
Earnings per share
-0.12
-0.12
-0.09
-0.09
Interest and investment income
658.00K
575.00K
793.00K
697.00K
Interest expense
-
-
-
-
Net interest expenses
658.00K
575.00K
793.00K
697.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.07M
-18.95M
-18.30M
-19.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps